深圳商报·读创客户端记者 马强据北交所官网信息，7月16日，北交所就天康制药股份有限公司（以下简称“天康制药”）IPO申请下发首轮审核问询函，涉及公司持续盈利能力、相对于控股股东独立性、经营合规性、大额应收款项及坏账准备计提充分性、募投项目的必要性与合理性等12大问题。▍为国内知名养殖企优质动物疫苗供应商，控股股东为上市公司天康生物招股书显示，天康制药主要从事兽用生物制品研发、生产、销售及技术转让...
Source Link深圳商报·读创客户端记者 马强据北交所官网信息，7月16日，北交所就天康制药股份有限公司（以下简称“天康制药”）IPO申请下发首轮审核问询函，涉及公司持续盈利能力、相对于控股股东独立性、经营合规性、大额应收款项及坏账准备计提充分性、募投项目的必要性与合理性等12大问题。▍为国内知名养殖企优质动物疫苗供应商，控股股东为上市公司天康生物招股书显示，天康制药主要从事兽用生物制品研发、生产、销售及技术转让...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.